{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:11:14Z","timestamp":1790633474977,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014012","name":"FightMND Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Neurosciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tins.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T12:24:45Z","timestamp":1786105485000},"page":"750-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interleukin-6 trans-signalling as a selectively targetable driver of neurodegeneration"],"prefix":"10.1016","volume":"49","author":[{"given":"Grace","family":"Risby-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-7396","authenticated-orcid":false,"given":"John D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny N.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tins.2026.07.002_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255533","article-title":"Interleukin 6: at the interface of human health and disease","volume":"14","author":"Grebenciucova","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12688\/f1000research.26058.1","article-title":"Interleukin-6 signalling in health and disease","volume":"9","author":"Rose-John","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.tins.2026.07.002_bb0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s11064-023-04085-6","article-title":"The role of IL-6 in neurodegenerative disorders","volume":"49","author":"Shan","year":"2024","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.tins.2026.07.002_bb0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2147\/ITT.S485684","article-title":"IL-6 signaling in immunopathology: from basic biology to selective therapeutic intervention","volume":"14","author":"Schumertl","year":"2025","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.tins.2026.07.002_bb0030","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1471-4159.2009.06366.x","article-title":"Context-dependent IL-6 potentiation of interferon-gamma-induced IL-12 secretion and CD40 expression in murine microglia","volume":"111","author":"Lin","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2026.07.002_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tins.2026.07.002_bb0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1172\/JCI200522433","article-title":"The IL-6R \u03b1 chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo","volume":"115","author":"Doganci","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tins.2026.07.002_bb0045","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/glia.22689","article-title":"Microglia-induced IL-6 protects against neuronal loss following HSV-1 infection of neural progenitor cells","volume":"62","author":"Chucair-Elliott","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.tins.2026.07.002_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.expneurol.2012.03.019","article-title":"IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation","volume":"236","author":"Yang","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tins.2026.07.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155654","article-title":"Role of IL-6 in the commitment of T cell subsets","volume":"146","author":"Korn","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.tins.2026.07.002_bb0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.tins.2026.07.002_bb0065","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","article-title":"Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis","volume":"182","author":"Nowell","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.tins.2026.07.002_bb0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","article-title":"TGF-\u03b2 suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling","volume":"21","author":"Becker","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.tins.2026.07.002_bb0080","article-title":"ADAM metalloproteinase domain 17 regulates cholestasis-associated liver injury and sickness behavior development in mice","volume":"12","author":"Almishri","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0085","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3390\/cancers11111736","article-title":"ADAM17 activity and IL-6 trans-signaling in inflammation and cancer","volume":"11","author":"Schumacher","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tins.2026.07.002_bb0090","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.0801217","article-title":"Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6\/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model","volume":"184","author":"Matsumoto","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110358","article-title":"Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological \u03b1-synuclein","volume":"38","author":"Sterling","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.tins.2026.07.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155832","article-title":"Interleukin-6 classic and trans-signaling utilize glucose metabolism reprogramming to achieve anti- or pro-inflammatory effects","volume":"155","author":"Xu","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.tins.2026.07.002_bb0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-019-0356-0","article-title":"Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: fusing experimental insights and dynamic modelling","volume":"17","author":"Reeh","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.tins.2026.07.002_bb0110","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3389\/fimmu.2017.01675","article-title":"Forward and reverse signaling mediated by transmembrane tumor necrosis factor-alpha and TNF receptor 2: potential roles in an immunosuppressive tumor microenvironment","volume":"8","author":"Qu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0115","doi-asserted-by":"crossref","DOI":"10.14293\/S2199-1006.1.SOR-LIFE.CLNG3MP.v1","article-title":"ADAM17 and its proteolytic targets in disease pathogenesis","author":"Amin","year":"2026","journal-title":"FEBS J."},{"key":"10.1016\/j.tins.2026.07.002_bb0120","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.4049\/jimmunol.179.4.2041","article-title":"Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells","volume":"179","author":"Dominitzki","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","article-title":"Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction","volume":"29","author":"Ogura","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.tins.2026.07.002_bb0130","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1073\/pnas.0802218105","article-title":"IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis","volume":"105","author":"Serada","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2026.07.002_bb0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jneuroim.2008.09.007","article-title":"IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier","volume":"205","author":"Linker","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0140","doi-asserted-by":"crossref","first-page":"C589","DOI":"10.1152\/ajpcell.00235.2017","article-title":"Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis","volume":"314","author":"Alsaffar","year":"2018","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.tins.2026.07.002_bb0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1074-7613(00)80334-9","article-title":"Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment","volume":"6","author":"Romano","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.tins.2026.07.002_bb0150","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/hmg\/ddx053","article-title":"Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma","volume":"26","author":"Farahi","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2026.07.002_bb0155","doi-asserted-by":"crossref","first-page":"C554","DOI":"10.1152\/ajpcell.00323.2020","article-title":"Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells","volume":"320","author":"Montgomery","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.tins.2026.07.002_bb0160","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1172\/JCI119821","article-title":"Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha","volume":"100","author":"Modur","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tins.2026.07.002_bb0165","doi-asserted-by":"crossref","first-page":"C556","DOI":"10.1152\/ajpcell.00171.2022","article-title":"SOCS3 limits TNF and endotoxin-induced endothelial dysfunction by blocking a required autocrine interleukin-6 signal in human endothelial cells","volume":"323","author":"Martino","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.tins.2026.07.002_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2018.09.009","article-title":"Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells","volume":"178","author":"Valle","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.tins.2026.07.002_bb0175","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1007\/s10753-022-01711-3","article-title":"Interleukin-6 downregulates the expression of vascular endothelial-cadherin and increases permeability in renal glomerular endothelial cells via the trans-signaling pathway","volume":"45","author":"Yang","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.tins.2026.07.002_bb0180","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbi.2025.06.021","article-title":"IL-6 trans-signalling is elevated in ALS models and drives TDP-43 induced inflammatory responses in microglia","volume":"129","author":"Risby-Jones","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tins.2026.07.002_bb0185","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","article-title":"Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain","volume":"34","author":"Campbell","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2026.07.002_bb0190","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2018.09.002","article-title":"Microglia priming by interleukin-6 signaling is enhanced in aged mice","volume":"324","author":"Garner","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0195","article-title":"Bystander activation of microglia by Brucella abortus-infected astrocytes induces neuronal death via IL-6 trans-signaling","volume":"14","author":"Rodriguez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbi.2019.08.005","article-title":"IL-6 trans-signaling in the brain influences the behavioral and physio-pathological phenotype of the Tg2576 and 3xTgAD mouse models of Alzheimer\u2019s disease","volume":"82","author":"Escrig","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tins.2026.07.002_bb0205","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/21678421.2020.1813310","article-title":"Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients","volume":"22","author":"Wosiski-Kuhn","year":"2021","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"10.1016\/j.tins.2026.07.002_bb0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/exnr.1995.1082","article-title":"Interleukin-1\u03b2 enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons","volume":"136","author":"Akaneya","year":"1995","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tins.2026.07.002_bb0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-020-00379-3","article-title":"Interleukin-6 deficiency exacerbates Huntington\u2019s disease model phenotypes","volume":"15","author":"Wertz","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.tins.2026.07.002_bb0220","article-title":"Neurodegeneration in multiple sclerosis","volume":"15","author":"Mey","year":"2023","journal-title":"WIREs Mech. Dis."},{"key":"10.1016\/j.tins.2026.07.002_bb0225","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jneuroim.2006.03.004","article-title":"IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles","volume":"175","author":"Malmestrom","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0230","first-page":"914","article-title":"IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients","volume":"7","author":"Stelmasiak","year":"2001","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.tins.2026.07.002_bb0235","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0165-5728(99)00120-4","article-title":"CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis","volume":"99","author":"Padberg","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0240","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1545968319868713","article-title":"Interleukin-6 disrupts synaptic plasticity and impairs tissue damage compensation in multiple sclerosis","volume":"33","author":"Stampanoni Bassi","year":"2019","journal-title":"Neurorehabil. Neural Repair"},{"key":"10.1016\/j.tins.2026.07.002_bb0245","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-019-01980-7","article-title":"The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"137","author":"Brambilla","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tins.2026.07.002_bb0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(96)00283-3","article-title":"IL-6 detection in multiple sclerosis brain","volume":"146","author":"Maimone","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.tins.2026.07.002_bb0255","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1468-1331.2000.00075.x","article-title":"Increased T-lymphocyte interleukin-6 binding in patients with multiple sclerosis","volume":"7","author":"Bongioanni","year":"2000","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tins.2026.07.002_bb0260","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/intimm\/10.5.703","article-title":"IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein","volume":"10","author":"Okuda","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0265","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.4049\/jimmunol.0900242","article-title":"Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis","volume":"183","author":"Quintana","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0270","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1089\/neu.2023.0135","article-title":"Interleukin-6 in traumatic brain injury: a Janus-faced player in damage and repair","volume":"40","author":"Ciryam","year":"2023","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.tins.2026.07.002_bb0275","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41467-020-20112-4","article-title":"Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice","volume":"12","author":"Leibinger","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tins.2026.07.002_bb0280","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cell.2020.02.013","article-title":"Repopulating microglia promote brain repair in an IL-6-dependent manner","volume":"180","author":"Willis","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tins.2026.07.002_bb0285","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tins.2026.07.002_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.758233","article-title":"Case report: arterial wall inflammation in atherosclerotic cardiovascular disease is reduced by olamkicept (sgp130Fc)","volume":"13","author":"Schulte","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tins.2026.07.002_bb0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/mus.27339","article-title":"Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients","volume":"64","author":"Milligan","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tins.2026.07.002_bb0300","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s13311-016-0461-3","article-title":"Combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: deleterious alteration of lipid metabolism","volume":"13","author":"Patin","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tins.2026.07.002_bb0305","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200095","article-title":"Levels of soluble interleukin 6 receptor and Asp358Ala are associated with cognitive performance and Alzheimer disease biomarkers","volume":"10","author":"Quillen","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.tins.2026.07.002_bb0310","article-title":"Cumulative evidence for associations between genetic variants in interleukin 6 receptor gene and human diseases and phenotypes","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0315","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/CIRCRESAHA.121.319589","article-title":"A missense variant in the IL-6 receptor and protection from peripheral artery disease","volume":"129","author":"Levin","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.tins.2026.07.002_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytox.2021.100058","article-title":"Exclusive inhibition of IL-6 trans-signaling by soluble gp130FlyRFc","volume":"3","author":"Berg","year":"2021","journal-title":"Cytokine X"},{"key":"10.1016\/j.tins.2026.07.002_bb0325","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.tins.2026.07.002_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc3480","article-title":"Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion","volume":"14","author":"Heise","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tins.2026.07.002_bb0335","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1785021","article-title":"Generation of soluble interleukin-11 and interleukin-6 receptors: a crucial function for proteases during inflammation","volume":"2016","author":"Lokau","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.tins.2026.07.002_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103309","article-title":"A single aromatic residue in sgp130Fc\/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling","volume":"24","author":"Lokau","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.tins.2026.07.002_bb0345","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41413-020-0098-z","article-title":"A variant in IL6ST with a selective IL-11 signaling defect in human and mouse","volume":"8","author":"Schwerd","year":"2020","journal-title":"Bone Res."},{"key":"10.1016\/j.tins.2026.07.002_bb0350","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000631","article-title":"IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis","volume":"6","author":"Wosiski-Kuhn","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.tins.2026.07.002_bb0355","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3390\/ijms20112759","article-title":"Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis?","volume":"20","author":"Moreno-Martinez","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tins.2026.07.002_bb0360","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fnins.2019.00574","article-title":"Increased interleukin-6 levels in the astrocyte-derived exosomes of sporadic amyotrophic lateral sclerosis patients","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tins.2026.07.002_bb0365","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/ijms19020423","article-title":"Potential role of humoral IL-6 cytokine in mediating pro-inflammatory endothelial cell response in amyotrophic lateral sclerosis","volume":"19","author":"Garbuzova-Davis","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tins.2026.07.002_bb0370","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.4049\/jimmunol.1000142","article-title":"IL-17 enhancement of the IL-6 signaling cascade in astrocytes","volume":"184","author":"Ma","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0375","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fimmu.2019.00801","article-title":"Circulating cytokines could not be good prognostic biomarkers in a mouse model of amyotrophic lateral sclerosis","volume":"10","author":"Moreno-Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0380","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/brainsci15010084","article-title":"Enhanced interleukin 6 trans-signaling modulates disease process in amyotrophic lateral sclerosis mouse models","volume":"15","author":"Milligan","year":"2025","journal-title":"Brain Sci."},{"key":"10.1016\/j.tins.2026.07.002_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrn2967","article-title":"Amyloid-\u03b2 and tau \u2013a toxic pas de deux in Alzheimer\u2019s disease","volume":"12","author":"Ittner","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tins.2026.07.002_bb0390","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10787-019-00580-x","article-title":"Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer\u2019s disease","volume":"27","author":"Kaur","year":"2019","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.tins.2026.07.002_bb0395","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbi.2023.06.027","article-title":"Associations of neuroinflammatory IL-6 and IL-8 with brain atrophy, memory decline, and core AD biomarkers \u2013 in cognitively unimpaired older adults","volume":"113","author":"Capogna","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tins.2026.07.002_bb0400","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41398-021-01349-z","article-title":"Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer\u2019s disease","volume":"11","author":"Lyra e Silva","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tins.2026.07.002_bb0405","doi-asserted-by":"crossref","DOI":"10.1159\/000547726","article-title":"Plasma IL-6 levels as a biomarker for behavioral changes in Alzheimer\u2019s disease","author":"Yasuno","year":"2025","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.tins.2026.07.002_bb0410","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bbi.2024.06.014","article-title":"Plasma IL-6 levels and their association with brain health and dementia risk: a population-based cohort study","volume":"120","author":"Zhao","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tins.2026.07.002_bb0415","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.4049\/jimmunol.181.10.7254","article-title":"Fibrillar amyloid-\u03b2 peptides activate microglia via TLR2: implications for Alzheimer\u2019s disease","volume":"181","author":"Jana","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0420","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.nbd.2008.12.007","article-title":"Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer\u2019s brain is mediated by the JNK-AP1 signaling pathway","volume":"34","author":"Vukic","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2026.07.002_bb0425","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yexcr.2004.01.002","article-title":"Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5\/p35 pathway","volume":"295","author":"Quintanilla","year":"2004","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tins.2026.07.002_bb0430","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0169-328X(97)00356-2","article-title":"Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor\/interleukin-6 complex","volume":"55","author":"Ringheim","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.tins.2026.07.002_bb0435","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/s41467-022-30461-x","article-title":"Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses","volume":"13","author":"Meng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tins.2026.07.002_bb0440","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1159\/000487876","article-title":"ADAM17-mediated ectodomain shedding of toll-like receptor 4 as a negative feedback regulation in lipopolysaccharide-activated aortic endothelial cells","volume":"45","author":"Yang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.tins.2026.07.002_bb0445","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1038\/s41467-026-73902-7","article-title":"GWAS on short tandem repeats identifies genetic mechanisms in Alzheimer\u2019s disease","volume":"17","author":"Gmelin","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tins.2026.07.002_bb0450","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/glia.24355","article-title":"Complement receptor 1 is expressed on brain cells and in the human brain","volume":"71","author":"Daskoulidou","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.tins.2026.07.002_bb0455","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","article-title":"Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease","volume":"43","author":"Hollingworth","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tins.2026.07.002_bb0460","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13024-023-00674-9","article-title":"Microglial function, INPP5D\/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer\u2019s disease","volume":"18","author":"Terzioglu","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.tins.2026.07.002_bb0465","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson\u2019s disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tins.2026.07.002_bb0470","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","article-title":"Role of dopamine in the pathophysiology of Parkinson\u2019s disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.tins.2026.07.002_bb0475","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41531-023-00449-5","article-title":"A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease","volume":"9","author":"Qu","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.tins.2026.07.002_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1104393","article-title":"Serum inflammatory cytokines levels and the correlation analyses in Parkinson\u2019s disease","volume":"11","author":"Fu","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tins.2026.07.002_bb0485","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0404.1998.tb01736.x","article-title":"Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson\u2019s disease","volume":"98","author":"Muller","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.tins.2026.07.002_bb0490","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1471-4159.2002.01131.x","article-title":"Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice","volume":"83","author":"Bolin","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2026.07.002_bb0495","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163359","article-title":"Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson\u2019s disease","volume":"9","author":"Pons-Espinal","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.tins.2026.07.002_bb0500","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","article-title":"Huntington\u2019s disease: diagnosis and management","volume":"22","author":"Stoker","year":"2022","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.tins.2026.07.002_bb0505","article-title":"Neuroinflammatory proteins in Huntington\u2019s disease: insights into mechanisms, diagnosis, and therapeutic implications","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tins.2026.07.002_bb0510","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tins.2026.07.002_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1088124","article-title":"Neuroinflammation in Huntington\u2019s disease: from animal models to clinical therapeutics","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tins.2026.07.002_bb0520","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","article-title":"The role of microglia and astrocytes in Huntington\u2019s disease","volume":"12","author":"Palpagama","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.tins.2026.07.002_bb0525","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/1570159X19666211201094608","article-title":"Neuroinflammation in Huntington\u2019s disease: a starring role for astrocyte and microglia","volume":"20","author":"Saba","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.tins.2026.07.002_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104963","article-title":"The contribution of glial cells to Huntington\u2019s disease pathogenesis","volume":"143","author":"Wilton","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2026.07.002_bb0535","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1523\/JNEUROSCI.3516-14.2015","article-title":"The JAK\/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer\u2019s and Huntington\u2019s diseases","volume":"35","author":"Ben Haim","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2026.07.002_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203837","article-title":"Cilostazol disrupts TLR-4, Akt\/GSK-3\u03b2\/CREB, and IL-6\/JAK-2\/STAT-3\/SOCS-3 crosstalk in a rat model of Huntington\u2019s disease","volume":"13","author":"El-Abhar","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.tins.2026.07.002_bb0545","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1742-2094-8-54","article-title":"Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior","volume":"8","author":"Burton","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tins.2026.07.002_bb0550","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0002-9440(10)64787-6","article-title":"Astrocytic alterations in interleukin-6\/soluble interleukin-6 receptor \u03b1 double-transgenic mice","volume":"157","author":"Brunello","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tins.2026.07.002_bb0555","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/cyto.2000.0831","article-title":"Directly linked soluble IL-6 receptor\u2013IL-6 fusion protein induces astrocyte differentiation from neuroepithelial cells via activation of STAT3","volume":"13","author":"Takizawa","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.tins.2026.07.002_bb0560","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#","article-title":"Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression","volume":"26","author":"Marz","year":"1999","journal-title":"Glia"},{"key":"10.1016\/j.tins.2026.07.002_bb0565","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13024-023-00596-6","article-title":"The Alzheimer\u2019s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130","volume":"18","author":"M\u00fcller","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.tins.2026.07.002_bb0570","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/107999099313974","article-title":"The IL-6\/sIL-6R fusion protein hyper-IL-6 promotes neurite outgrowth and neuron survival in cultured enteric neurons","volume":"19","author":"Schafer","year":"1999","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.tins.2026.07.002_bb0575","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41386-025-02320-y","article-title":"Synaptic effects of interleukin-6 on human iPSC-derived dopaminergic neurons","volume":"51","author":"Huang","year":"2026","journal-title":"Neuropsychopharmacology"}],"container-title":["Trends in Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166223626001402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166223626001402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:36:19Z","timestamp":1788881779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166223626001402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":115,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0166223626001402"],"URL":"https:\/\/doi.org\/10.1016\/j.tins.2026.07.002","relation":{},"ISSN":["0166-2236"],"issn-type":[{"value":"0166-2236","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 trans-signalling as a selectively targetable driver of neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Trends in Neurosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tins.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}